YAP1 and cancer: However, distinct core Hippo pathway components are mutated only in a subset of cancers, and the underlying reasons as to why YAP/TAZ are predominantly nuclear in solid tumours are not fully understood (Moroishi et al, 2015a; Fulford et al, 2018; Rognoni & Walko, 2019; Salem & Hansen, 2019; Zanconato et al, 2019; Thompson, 2020).